Navigation Links
Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
Date:3/18/2008

MONTREAL, March 18 /PRNewswire/ - Aegera Therapeutics announced today the initiation of a Phase 1, first-in-man, clinical trial for AEG33773, a novel, orally bioavailable small molecule in development for the treatment of painful diabetic neuropathy. The Phase I study will evaluate the safety, tolerability and pharmacokinetic profile of AEG33773 using a randomized, double blind, placebo controlled, single ascending dose design in healthy male volunteers.

Aegera completed a comprehensive pre-clinical development program on AEG33773, culminating in regulatory clearance from Health Canada and treatment of a first patient, in less than 12 months.

"We are extremely excited about the potential for AEG33773 to treat painful diabetic neuropathy and to expand to other pain and neuropathy indications, based on our extensive preclinical experience with this family of compounds in multiple models of pain and neuropathy," commented Dr. Jon Durkin, Vice-President Research and Preclinical Development at Aegera.

"This important milestone was achieved in record time, as the Aegera team has successfully filed regulatory applications for two potential blockbuster compounds, AEG33773 and AEG40826, in the last three months while initiating multiple Phase 2 trials for our lead program AEG35156. Aegera now has four unique programs in clinical development and is poised to deliver significant clinical data over the next 12-18 months" added Dr. Michael J. Berendt, Aegera's President and CEO.

About AEG33773

AEG33773 was developed as an orally bioavailable small molecule compound which provides acute pain relief in preclinical models of neuropathic and inflammatory pain. In addition, AEG33773's unique mechanism of action has demonstrated excellent in vivo activity in models of diabetic neuropathy with respect to its ability to not only prevent, but also to reverse established neuropathies.

About Aegera Therapeutics Inc.

Aegera Therapeutic
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
4. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
8. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
9. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
10. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
11. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...lif.,Nov.24/PRNewswire-FirstCall/--NeurogesX,Inc.(...evelopingandcommercializingnovelpainmanagementther...dChiefExecutiveOfficer,isscheduledtopresentatthe21...ecember1-2,2009atTheNewYorkPalaceHotelinNewYork,Ne...nancialOfficer,willbeavailabletorespondtoquestions...
(Date:11/24/2009)...cacyendpointhasbeenmetforpatientswithadvanced-stag...Nov.24/PRNewswire-FirstCall/-AEternaZentarisInc.(N...maceuticalcompanyfocusedonendocrinetherapyandoncol...tudywithitstargetedcytotoxicpeptideconjugate,AEZS-...entendometrialcancer.Inapersonalizedhealthcareappr...
(Date:11/24/2009)...,Calif.,Nov.24/PRNewswire-FirstCall/--GenomicHealt...GenomicHealth,sExecutiveChairman,willpresentatthe2...CityonTuesday,December1,2009at10:00a.m.ET. ,, T...resentation,visittheInvestorRelationssectionofGeno....com .Pleaseconnecttothewebsiteatleast15minutespri...
(Date:11/24/2009)....24/PRNewswire-FirstCall/--CellTherapeutics,Inc.(C...stAnnualPiperJaffrayHealthCareConference.Theconfer...otel. ,, CTIwillpresentonTuesday,December1at11:...castofCTI,spresentationwillbeavailableat www.cellt...afterwards. , ,PiperJaffrayHealthCareConference,N...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Genomic Health to Present at Piper Jaffray Health Care Conference 2
...rience In Molecular Diagnostics , , SALT LAKE CIT...ionizing spine care through the development of mol...at Roberto A. Macina, Ph.D., has joined the execut...ident of Research and Development. Dr. Macina will...nd Chief Scientific Officer for Axial Biotech. , ...
...hew, Inc.,(NYSE: SNN , LSE: SN) Orthopaedic Reco...uction of VISIONAIRE Patient Matched instrumentati...VISIONAIRE system is proprietary technology that,u...rgical instrumentation for,use with the Smith &...ts. , By using instruments designed from each ...
... Bulletin Board: TBIO) is canceling the following ... Fourth Quarter 2008 Earnings Release, ...ebruary 25, 2009 @ 5:00 p.m. Eastern, Conta... Transgenomic will communicate by Press Release as...rth Quarter 2008 Earnings Release Conference Call ...
Other Biology Technology:Axial Biotech Appoints Dr. Roberto Macina to Vice President of Research and Development 2Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement 2Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement 3
(Date:11/25/2009)...mber 11, firefighters, police officers and ambulan... World Trade Center complex. They battled to save ...or survivors, tackled fires and evacuated as many ... estimated 17,000 people. And making their jobs ev...frightened workers and their relatives jammed mobi...
(Date:11/25/2009)... State University assistant professors recently re...n (NSF) to continue research beneficial to underst...0,000. , Christopher Blackwood, assistant profes...awarded grants to support two separate research pr...Litter Decomposer Communities and Functions from t...
(Date:11/24/2009)...cience is opening new doors to understanding how s...hearing of a marine mammal or if they hear it at ...-ray scanners that NASA uses to detect flaws in th...ow allowing scientists to peek inside the giant he...ree-dimensional replicas of a whale,s hearing anat...
Breaking Biology News(10 mins):Magic box for mission impossible 2Magic box for mission impossible 3Kent State University professors focus research on the environment with grants totaling $890,000 2Rocket science leads to new whale discovery 2John C Moran Named CEO at Core Essence Orthopaedics 56930 1John C Moran Named CEO at Core Essence Orthopaedics 56930 2Alliance Between Centro Mater and Navarro Discount Pharmacies 56927 1Alliance Between Centro Mater and Navarro Discount Pharmacies 56927 2American Lung Association Supports Health Officials to Prevent the Spread of Seasonal Influenza by Urging People to Get Vaccinated 56924 1American Lung Association Supports Health Officials to Prevent the Spread of Seasonal Influenza by Urging People to Get Vaccinated 56924 2American Lung Association Supports Health Officials to Prevent the Spread of Seasonal Influenza by Urging People to Get Vaccinated 56924 3American Lung Association Supports Health Officials to Prevent the Spread of Seasonal Influenza by Urging People to Get Vaccinated 56924 4
...tomobile, even during an economic downturn. Every ...s to visit remote places, to commute, and to reach... roads amounts to trillions of dollars and million...ty of Arizona, Tucson suggests this is an apparent...on, congestion, delays, and the fundamental reason...
...ans, have separate sexes they are born, live out ... However, some animals live as one sex in part of ...a phenomenon called sequential hermaphroditism. Wh... is why the phenomenon is so rare, since their ana...es rarely outweigh the advantages. , A report by ...
...f Environmental Health Sciences (NIEHS), part of t...ity have discovered a cause of airway irritation a...n air pollutant. Using an animal model, the resear...top the airways from narrowing. These findings hel...ay eventually help physicians better treat emergen...
Other Biology News:Defectors take the car, cooperators go by bus 2Why don't more animals change their sex? 2Research finds new cause of ozone wheezing and potential treatments 2
...ujifilm Life Science FLA-8000 Fluorescent Image An... detection in a single laser imaging system. This ...les labeled with fluorescent dyes or radioisotopes...nding laboratories. Speed, image quality and flexi...
Capillary Electrophoresis System from Agilent Technologies
Experion Spin Filters, 10 from Bio-Rad
...embrane filters suitable for use in the Microsart ...per on top of each filter, in a specially designed...ting of the band of membrane filter units ensures ...hape of the sealed band guarantees uniform dispens...
Biology Products: